@dachopper
You are absolutely correct, this is because the NYHA classification is very subjective. See below of an extract from an article:
"The survey of cardiologists showed no consistent method for assessing NYHA class and a literature survey showed that 99% of research papers do not reference or describe their methods for assigning NYHA classes. The interoperator variability study showed only 54% concordance between the two cardiologists."
However, no one can miss diabetic/ischemic classification; furthermore, there seems to be a bidirectional link between diabetes and heart-failure. exert from this article write: "People who have Type 2 diabetes, characterized by elevated blood sugar levels, are two to four times more likely to develop heart failure than someone without diabetes. But heart failure, a condition in which the heart fails to efficiently pump oxygenated blood through the body, also is a risk factor for diabetes"
I also agree with you that our target population for the next trial should be 1) CRP >2 (inflammation), 2) NYHA class II - III (but the study will enriched for class II, as many class III patients have too much scare tissues already in the heart) 3) diabetic/ischemic patients (either as an inclusion criteria OR as a pre-specified subpopulation)
Ideally we would ignore class III patients, but since it is so difficult to discern between class II & III, it is wiser to include both into the next trial, whatever the next trial may be (either another phase 3; or a phase 4 (slim chance)- if we get Accelerated Approval for the diabetic/ischemic group).
The meeting with the FDA will be interesting, because if we have to wait for another phase 3 trial, that's at least 4-5 years before we see any results, during which more patients would have died from HF.
- Forums
- ASX - By Stock
- MSB
- Ann: Biotech Showcase 2022 Presentation
Ann: Biotech Showcase 2022 Presentation, page-14
-
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.07 |
Change
-0.025(2.29%) |
Mkt cap ! $1.216B |
Open | High | Low | Value | Volume |
$1.10 | $1.10 | $1.06 | $4.942M | 4.613M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 70659 | $1.07 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.07 | 43531 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 70659 | 1.065 |
10 | 321922 | 1.060 |
10 | 163165 | 1.055 |
18 | 145872 | 1.050 |
5 | 82472 | 1.045 |
Price($) | Vol. | No. |
---|---|---|
1.070 | 43531 | 2 |
1.075 | 45000 | 1 |
1.080 | 12400 | 2 |
1.085 | 37622 | 4 |
1.090 | 28097 | 2 |
Last trade - 16.10pm 20/06/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
HAR
HARANGA RESOURCES LIMITED.
Peter Batten, MD
Peter Batten
MD
Previous Video
Next Video
SPONSORED BY The Market Online